Adaptive Biotechnologies Corp
ADPT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001478320
In the last 90 days, Adaptive Biotechnologies Corp insiders filed 0 open-market purchases and 11 sales; 301 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; superinvestors Viking Global Investors and ARK Invest hold it.
Q2 2024 vs. Q1 2024
How the institutions holding Adaptive Biotechnologies Corp changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 190 | 1 | 177 | −12 |
| Shares | 142.6M | 144.7K | 148.8M | +6.37M (+4.5%) |
| Value | $457.4M | $464.6K | $538.6M | +$81.6M (+17.9%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (25)
Institutions that held Adaptive Biotechnologies Corp at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (37)
Institutions that held Adaptive Biotechnologies Corp at the end of Q1 2024 and filed for Q2 2024 without it.
Not filed for Q2 2024 yet (1)
Institutions that held Adaptive Biotechnologies Corp at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 144,726 | $464.6K |